What is the current valuation of the Hepatitis Therapeutic Market as of 2024?

The Hepatitis Therapeutic Market was valued at 46.37 USD Billion in 2024. Read More

What is the projected market size for the Hepatitis Therapeutic Market by 2035?

The market is projected to reach 107.59 USD Billion by 2035. Read More

What is the expected CAGR for the Hepatitis Therapeutic Market during the forecast period 2025 - 2035?

The expected CAGR for the Hepatitis Therapeutic Market during 2025 - 2035 is 7.95%. Read More

Which companies are the key players in the Hepatitis Therapeutic Market?

Key players include Gilead Sciences, AbbVie, Merck & Co, Bristol-Myers Squibb, Johnson & Johnson, Roche, GlaxoSmithKline, Novartis, and AstraZeneca. Read More

What are the main segments of the Hepatitis Therapeutic Market?

The main segments include Treatment Line, Spectrum of Disease, Subtypes of Hepatitis, Drug Class, and Route of Administration. Read More

How does the 1st Line Treatment segment perform in terms of market valuation?

The 1st Line Treatment segment is valued between 30.0 and 70.0 USD Billion. Read More

What is the market valuation for Chronic Hepatitis within the Spectrum of Disease segment?

Chronic Hepatitis is valued between 20.0 and 46.0 USD Billion within the Spectrum of Disease segment. Read More

What are the projected valuations for Hepatitis B and Hepatitis C by 2035?

Hepatitis B is projected to be valued between 18.55 and 42.0 USD Billion, while Hepatitis C is expected to reach between 27.82 and 65.59 USD Billion. Read More

What is the market size for Antivirals in the Drug Class segment?

The Antivirals segment is valued between 30.0 and 70.0 USD Billion. Read More

What is the expected market performance for Oral and Injectable routes of administration?

The Oral route is valued between 20.0 and 45.0 USD Billion, while the Injectable route is projected to be between 26.37 and 62.59 USD Billion. Read More

Hepatitis Therapeutic Market

ID: MRFR/HC/27716-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Hepatitis Therapeutic Market Research Report: Size, Share, Trend Analysis By Treatment Line (1st Line Treatment, 2nd Line Treatment and Beyond), By Spectrum of Disease (Chronic Hepatitis, Decompensated Cirrhosis, Hepatocellular Carcinoma), By Subtypes of Hepatitis (Hepatitis B (HBV), Hepatitis C (HCV), By Drug Class (Antivirals, Immunomodulators), By Route of Administration (Oral, Injectable) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Hepatitis Therapeutic Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Line (USD Billion)
  1. 4.1.1 1st Line Treatment
  2. 4.1.2 2nd Line Treatment and Beyond
2. 4.2 Healthcare, BY Spectrum of Disease (USD Billion)
  1. 4.2.1 Chronic Hepatitis
  2. 4.2.2 Decompensated Cirrhosis
  3. 4.2.3 Hepatocellular Carcinoma
3. 4.3 Healthcare, BY Subtypes of Hepatitis (USD Billion)
  1. 4.3.1 Hepatitis B (HBV)
  2. 4.3.2 Hepatitis C (HCV)
4. 4.4 Healthcare, BY Drug Class (USD Billion)
  1. 4.4.1 Antivirals
  2. 4.4.2 Immunomodulators
5. 4.5 Healthcare, BY Route of Administration (USD Billion)
  1. 4.5.1 Oral
  2. 4.5.2 Injectable
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 AbbVie (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck & Co (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Roche (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 GlaxoSmithKline (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT LINE
4. 6.4 US MARKET ANALYSIS BY SPECTRUM OF DISEASE
5. 6.5 US MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
6. 6.6 US MARKET ANALYSIS BY DRUG CLASS
7. 6.7 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT LINE
9. 6.9 CANADA MARKET ANALYSIS BY SPECTRUM OF DISEASE
10. 6.10 CANADA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
11. 6.11 CANADA MARKET ANALYSIS BY DRUG CLASS
12. 6.12 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT LINE
15. 6.15 GERMANY MARKET ANALYSIS BY SPECTRUM OF DISEASE
16. 6.16 GERMANY MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
17. 6.17 GERMANY MARKET ANALYSIS BY DRUG CLASS
18. 6.18 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
19. 6.19 UK MARKET ANALYSIS BY TREATMENT LINE
20. 6.20 UK MARKET ANALYSIS BY SPECTRUM OF DISEASE
21. 6.21 UK MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
22. 6.22 UK MARKET ANALYSIS BY DRUG CLASS
23. 6.23 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
24. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT LINE
25. 6.25 FRANCE MARKET ANALYSIS BY SPECTRUM OF DISEASE
26. 6.26 FRANCE MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
27. 6.27 FRANCE MARKET ANALYSIS BY DRUG CLASS
28. 6.28 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
29. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT LINE
30. 6.30 RUSSIA MARKET ANALYSIS BY SPECTRUM OF DISEASE
31. 6.31 RUSSIA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
32. 6.32 RUSSIA MARKET ANALYSIS BY DRUG CLASS
33. 6.33 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
34. 6.34 ITALY MARKET ANALYSIS BY TREATMENT LINE
35. 6.35 ITALY MARKET ANALYSIS BY SPECTRUM OF DISEASE
36. 6.36 ITALY MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
37. 6.37 ITALY MARKET ANALYSIS BY DRUG CLASS
38. 6.38 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
39. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT LINE
40. 6.40 SPAIN MARKET ANALYSIS BY SPECTRUM OF DISEASE
41. 6.41 SPAIN MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
42. 6.42 SPAIN MARKET ANALYSIS BY DRUG CLASS
43. 6.43 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT LINE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY SPECTRUM OF DISEASE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TREATMENT LINE
51. 6.51 CHINA MARKET ANALYSIS BY SPECTRUM OF DISEASE
52. 6.52 CHINA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
53. 6.53 CHINA MARKET ANALYSIS BY DRUG CLASS
54. 6.54 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
55. 6.55 INDIA MARKET ANALYSIS BY TREATMENT LINE
56. 6.56 INDIA MARKET ANALYSIS BY SPECTRUM OF DISEASE
57. 6.57 INDIA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
58. 6.58 INDIA MARKET ANALYSIS BY DRUG CLASS
59. 6.59 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
60. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT LINE
61. 6.61 JAPAN MARKET ANALYSIS BY SPECTRUM OF DISEASE
62. 6.62 JAPAN MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
63. 6.63 JAPAN MARKET ANALYSIS BY DRUG CLASS
64. 6.64 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT LINE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY SPECTRUM OF DISEASE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
70. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT LINE
71. 6.71 MALAYSIA MARKET ANALYSIS BY SPECTRUM OF DISEASE
72. 6.72 MALAYSIA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
73. 6.73 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
74. 6.74 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
75. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT LINE
76. 6.76 THAILAND MARKET ANALYSIS BY SPECTRUM OF DISEASE
77. 6.77 THAILAND MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
78. 6.78 THAILAND MARKET ANALYSIS BY DRUG CLASS
79. 6.79 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
80. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT LINE
81. 6.81 INDONESIA MARKET ANALYSIS BY SPECTRUM OF DISEASE
82. 6.82 INDONESIA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
83. 6.83 INDONESIA MARKET ANALYSIS BY DRUG CLASS
84. 6.84 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
85. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT LINE
86. 6.86 REST OF APAC MARKET ANALYSIS BY SPECTRUM OF DISEASE
87. 6.87 REST OF APAC MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
88. 6.88 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
89. 6.89 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT LINE
92. 6.92 BRAZIL MARKET ANALYSIS BY SPECTRUM OF DISEASE
93. 6.93 BRAZIL MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
94. 6.94 BRAZIL MARKET ANALYSIS BY DRUG CLASS
95. 6.95 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
96. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT LINE
97. 6.97 MEXICO MARKET ANALYSIS BY SPECTRUM OF DISEASE
98. 6.98 MEXICO MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
99. 6.99 MEXICO MARKET ANALYSIS BY DRUG CLASS
100. 6.100 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
101. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT LINE
102. 6.102 ARGENTINA MARKET ANALYSIS BY SPECTRUM OF DISEASE
103. 6.103 ARGENTINA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
104. 6.104 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
105. 6.105 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT LINE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY SPECTRUM OF DISEASE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT LINE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY SPECTRUM OF DISEASE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT LINE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY SPECTRUM OF DISEASE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
122. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT LINE
123. 6.123 REST OF MEA MARKET ANALYSIS BY SPECTRUM OF DISEASE
124. 6.124 REST OF MEA MARKET ANALYSIS BY SUBTYPES OF HEPATITIS
125. 6.125 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
126. 6.126 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TREATMENT LINE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TREATMENT LINE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY SPECTRUM OF DISEASE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY SPECTRUM OF DISEASE, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY SUBTYPES OF HEPATITIS, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY SUBTYPES OF HEPATITIS, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.2.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.2.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.2.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.2.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.3.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.3.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.3.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.3.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.4.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.4.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.4.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.4.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.5.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.5.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.5.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.5.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.6.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.6.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.6.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.6.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.7.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.7.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.7.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.7.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.8.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.8.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.8.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.8.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.9.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.9.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.9.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.9.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.10.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.10.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.10.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.10.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.11.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.11.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.11.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.11.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.12.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.12.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.12.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.12.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.13.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.13.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.13.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.13.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.14.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.14.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.14.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.14.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.15.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.15.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.15.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.15.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.16.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.16.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.16.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.16.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.17.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.17.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.17.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.17.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.18.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.18.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.18.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.18.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.19.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.19.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.19.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.19.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.20.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.20.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.20.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.20.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.21.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.21.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.21.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.21.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.22.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.22.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.22.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.22.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.23.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.23.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.23.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.23.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.24.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.24.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.24.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.24.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.25.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.25.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.25.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.25.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.26.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.26.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.26.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.26.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.27.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.27.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.27.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.27.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.28.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.28.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.28.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.28.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.29.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.29.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.29.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.29.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT LINE, 2025-2035 (USD Billion)
  2. 7.30.2 BY SPECTRUM OF DISEASE, 2025-2035 (USD Billion)
  3. 7.30.3 BY SUBTYPES OF HEPATITIS, 2025-2035 (USD Billion)
  4. 7.30.4 BY DRUG CLASS, 2025-2035 (USD Billion)
  5. 7.30.5 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Treatment Line (USD Billion, 2025-2035)

1st Line Treatment
2nd Line Treatment and Beyond

Healthcare By Spectrum of Disease (USD Billion, 2025-2035)

Chronic Hepatitis
Decompensated Cirrhosis
Hepatocellular Carcinoma

Healthcare By Subtypes of Hepatitis (USD Billion, 2025-2035)

Hepatitis B (HBV)
Hepatitis C (HCV)

Healthcare By Drug Class (USD Billion, 2025-2035)

Antivirals
Immunomodulators

Healthcare By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓